Update: On March 28, 2018, Chugai Pharmaceuticals, a subsidiary of Roche, announced that a Japanese court ruled that the hemophilia treatment product Hemlibra (emicizumab) does not infringe on a patent held by Shire. Hemlibra has been approved in several jurisdictions for prophylaxis in patients with hemophilia A who have inhibitors. There are ongoing lawsuits on this patent issue in other countries.
The World Federation of Hemophilia has been closely monitoring the developing situation between Shire and Roche/Genentech and their dispute over patent ownership for Hemlibra. We will continue to do so and to inform our community of any developments as they become public.
In this situation, the WFH is concerned that all parties involved will not be able to resolve their dispute and ensure that access to treatment is not affected.
We will be sharing information distributed by both parties.